OMER

Omeros Corporation (NASDAQ:OMER) is a commercial-stage biopharmaceutical company founded in 1994 and headquartered in Seattle, Washington. The company went public in 2009 and focuses on discovering, developing, and commercializing innovative therapeutics for rare diseases, particularly those involving complement-mediated disorders, inflammatory conditions, and addictive behaviors. Omeros has evolved from a research-stage company to having one commercialized product generating royalty revenue, while advancing multiple late-stage clinical programs targeting significant unmet medical needs in orphan disease markets.